// App-Quantinova.ai

295 : Dose-escalation and dose-expansion study of trastuzumab deruxtecan (T-DXd) monotherapy and combinations in patients (pts) with advanced/metastatic HER2+ gastric cancer (GC)/gastroesophageal junction adenocarcinoma (GEJA): DESTINY-Gastric03.

Researchers

Presenter

  • Yelena Y. Janjigian

Principal Investigators

  • Do-Youn Oh

  • Sun Young Rha

  • Keun Wook Lee

  • Neeltje Steeghs

  • Yee Chao

  • Maria Di Bartolomeo

  • Marc Dez Garcia

  • Nadia Haj Mohammad

  • Alexander Stein

  • William McAdoo

  • Megan Winter

  • Liz Croydon

  • Jeeyun Lee

Medical Centers

  • Memorial Sloan Kettering Cancer Center, Port Washington, NY

  • Seoul National University Hospital, Seoul National University College of Medicine, Seoul, Korea

  • Yonsei Cancer Center, Seoul, Korea

  • Seoul National University College of Medicine, Seoul National University Bundang Hospital, Seongnam,...

  • Netherlands Cancer Institute (NKI), Amsterdam, Netherlands

  • Taipei Veterans General Hospital, National Yang-Ming University, Taipei, Taiwan

  • Fondazione IRCCS Istituto Nazionale dei Tumori, Milan, Italy

  • Vall d'Hebron University Hospital, Barcelona, Spain

  • University Medical Center Utrecht, Utrecht University, Utrecht, Netherlands

  • Hematology Oncology Practice Eppendorf, and University Cancer Center Hamburg, Hamburg, Germany

  • AstraZeneca Pharmaceuticals, Gaithersburg, MD

  • Astex Pharmaceutical, Inc., Cambridge, United Kingdom.

  • Samsung Medical Center, Sungkyunkwan University School of Medicine, Seoul, Korea

Locations

  • United States

  • Republic of South Korea

  • Netherlands

  • Taiwan

  • Italy

  • Spain

  • Germany

  • United Kingdom

Companies

  • N/A

Study Components

Therapeutic Area

  • Oncology (ONC)

Disease

  • Gastroesophageal junction (GEJ) adenocarcinoma

  • Gastric Cancer

  • Solid malignancies

Biomarkers

  • erb-b2 receptor tyrosine kinase 2

Drug/Treatment

  • Trastuzumab

Outcome

  • N/A

Study Design

  • Open Label

  • Multicenteric

  • Expansion Study

  • Dose Escalation

Phase

  • N/A

Study Id's

  • NCT04379596

Sponsors

  • N/A

Result

  • N/A

Copyright © 2026. QuantiNova All rights reserved